Marc Steven Hanover - Net Worth and Insider Trading

Marc Steven Hanover Net Worth

The estimated net worth of Marc Steven Hanover is at least $10,387 dollars as of 2024-04-23. Marc Steven Hanover is the CEO of Oncternal Therapeutics Inc and owns about 1,185 shares of Oncternal Therapeutics Inc (ONCT) stock worth over $10,387. Details can be seen in Marc Steven Hanover's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Marc Steven Hanover has not made any transactions after 2018-01-05 and currently still holds the listed stock(s).

Transaction Summary of Marc Steven Hanover

To

Marc Steven Hanover Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Marc Steven Hanover owns 1 companies in total, including Oncternal Therapeutics Inc (ONCT) .

Click here to see the complete history of Marc Steven Hanover’s form 4 insider trades.

Insider Ownership Summary of Marc Steven Hanover

Ticker Comapny Transaction Date Type of Owner
ONCT Oncternal Therapeutics Inc 2018-01-05 director & Interim CEO & President and COO

Marc Steven Hanover Latest Holdings Summary

Marc Steven Hanover currently owns a total of 1 stock. Marc Steven Hanover owns 1,185 shares of Oncternal Therapeutics Inc (ONCT) as of January 5, 2018, with a value of $10,387.

Latest Holdings of Marc Steven Hanover

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ONCT Oncternal Therapeutics Inc 2018-01-05 1,185 8.77 10,387

Holding Weightings of Marc Steven Hanover


Marc Steven Hanover Form 4 Trading Tracker

According to the SEC Form 4 filings, Marc Steven Hanover has made a total of 0 transactions in Oncternal Therapeutics Inc (ONCT) over the past 5 years. The most-recent trade in Oncternal Therapeutics Inc is the sale of 52 shares on January 5, 2018, which brought Marc Steven Hanover around $82,811.

Insider Trading History of Marc Steven Hanover

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Marc Steven Hanover Trading Performance

GuruFocus tracks the stock performance after each of Marc Steven Hanover's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Marc Steven Hanover is 22.88%. GuruFocus also compares Marc Steven Hanover's trading performance to market benchmark return within the same time period. The performance of stocks bought by Marc Steven Hanover within 3 months outperforms 4 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Marc Steven Hanover's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Marc Steven Hanover

Average Return

-0.73%

Average return per transaction

Outperforming Transactions

50%

2 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 18.33 22.88 5.98 -0.73 53.52 -45.2
Relative Return to S&P 500(%) 17.01 12.6 -8.29 -21.13 31.42 -56.95

Marc Steven Hanover Ownership Network

Ownership Network List of Marc Steven Hanover

No Data

Ownership Network Relation of Marc Steven Hanover


Marc Steven Hanover Owned Company Details

What does Oncternal Therapeutics Inc do?

Who are the key executives at Oncternal Therapeutics Inc?

Marc Steven Hanover is the director & Interim CEO & President and COO of Oncternal Therapeutics Inc. Other key executives at Oncternal Therapeutics Inc include director & Executive Chairman Robert James Wills , Chief Scientific Officer Gunnar F. Kaufmann , and Chief Medical Officer Salim Yazji .

Oncternal Therapeutics Inc (ONCT) Insider Trades Summary

Over the past 18 months, Marc Steven Hanover made no insider transaction in Oncternal Therapeutics Inc (ONCT). Other recent insider transactions involving Oncternal Therapeutics Inc (ONCT) include a net purchase of 9,020 shares made by Robert James Wills , a net purchase of 150,000 shares made by James B Breitmeyer , and a net purchase of 30,000 shares made by Richard G Vincent .

In summary, during the past 3 months, insiders sold 980 shares of Oncternal Therapeutics Inc (ONCT) in total and bought 10,980 shares, with a net purchase of 10,000 shares. During the past 18 months, 980 shares of Oncternal Therapeutics Inc (ONCT) were sold and 23,880 shares were bought by its insiders, resulting in a net purchase of 22,900 shares.

Oncternal Therapeutics Inc (ONCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Oncternal Therapeutics Inc Insider Transactions

No Available Data

Marc Steven Hanover Mailing Address

Above is the net worth, insider trading, and ownership report for Marc Steven Hanover. You might contact Marc Steven Hanover via mailing address: 175 Toyota Plaza, 7th Floor, Memphis Tn 38103.

Discussions on Marc Steven Hanover

No discussions yet.